Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Cullinan Therapeutics (Nasdaq: CGEM), a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York.
The company's CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones, M.D., M.B.A., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. ET. Investors and interested parties can access the webcast through the Events and Presentations section of Cullinan's investor relations website.
Cullinan Therapeutics (Nasdaq: CGEM), una compagnia biofarmaceutica specializzata in terapie mirate indipendentemente dalla loro modalità d'azione, ha annunciato la sua partecipazione alla prossima Guggenheim Securities SMID Cap Biotech Conference a New York.
Il CEO dell'azienda Nadim Ahmed e il Chief Medical Officer Jeffrey Jones, M.D., M.B.A., parteciperanno a un incontro informale programmato per mercoledì 5 febbraio 2025, alle 9:30 ET. Gli investitori e le parti interessate possono accedere al webcast tramite la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM), una compañía biofarmacéutica especializada en terapias dirigidas sin importar la modalidad, ha anunciado su participación en la próxima Guggenheim Securities SMID Cap Biotech Conference en Nueva York.
El CEO de la empresa Nadim Ahmed y el Director Médico Jeffrey Jones, M.D., M.B.A., participarán en una charla informal programada para miércoles 5 de febrero de 2025, a las 9:30 a.m. ET. Los inversores y partes interesadas pueden acceder al webcast a través de la sección de Eventos y Presentaciones del sitio web de relaciones con inversores de Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM), 모드에 관계없이 표적 치료제를 전문으로 하는 생명공학 회사가 뉴욕에서 열리는 Guggenheim Securities SMID Cap Biotech Conference에 참여한다고 발표했습니다.
회사의 CEO인 Nadim Ahmed와 최고 의료 책임자 Jeffrey Jones, M.D., M.B.A.가 2025년 2월 5일 수요일, 오전 9시 30분 ET에 예정된 파이어사이드 채팅에 참여할 것입니다. 투자자와 관심 있는 당사자는 Cullinan의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 웹캐스트에 접속할 수 있습니다.
Cullinan Therapeutics (Nasdaq: CGEM), une entreprise biopharmaceutique spécialisée dans des thérapies ciblées, quelle que soit la modalité, a annoncé sa participation à la prochaine Guggenheim Securities SMID Cap Biotech Conference à New York.
Le PDG de l'entreprise Nadim Ahmed et le directeur médical Jeffrey Jones, M.D., M.B.A. participeront à une discussion informelle prévue pour le mercredi 5 février 2025, à 9h30 ET. Les investisseurs et les parties intéressées peuvent accéder au webinaire via la section Événements et Présentations du site web des relations avec les investisseurs de Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM), ein biopharmazeutisches Unternehmen, das sich auf modality-agnostische zielgerichtete Therapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference in New York angekündigt.
Der CEO des Unternehmens Nadim Ahmed und der Chief Medical Officer Jeffrey Jones, M.D., M.B.A. werden an einem geplanten Fireside-Chat teilnehmen, der am Mittwoch, den 5. Februar 2025, um 9:30 Uhr ET stattfinden wird. Investoren und Interessierte können über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Cullinan auf den Webcast zugreifen.
- None.
- None.
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.
The fireside chat is scheduled for Wednesday, February 5, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When is Cullinan Therapeutics (CGEM) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Cullinan Therapeutics' (CGEM) Guggenheim conference presentation?
Which executives from Cullinan Therapeutics (CGEM) will participate in the Guggenheim Biotech Conference?
Where is the Guggenheim Securities SMID Cap Biotech Conference 2025 being held?
